A postbiotic solution that may help reduce the load of H. pylori in the stomach
Pylopass™ is a safe, natural solution to managing this common gastric microbial contamination. With its highly targeted co-aggregation ability, Pylopass™ can reduce the load of H. pylori in the stomach, which may lead to reduced symptoms of gastric inflammation.
H. pylori is prevalent across the globe
People who have H. pylori may have to make lifestyle changes such as changing their eating habits, exercising more, and maintaining a restrictive diet.
of the global population is infected with H. pylori.1
recognizes H. pylori as a risk factor for antibiotic resistance.4
of people with H. pylori live with a range of gastric upset symptoms and endure a lack of freedom in day-to-day dietary choices.10
What is H. pylori?
Helicobacter pylori or H. pylori is a gram negative, spiral-shaped bacterium able to infect the epithelial lining of the stomach and adhere to the mucosa. It is caused by ingesting contaminated food or water, or by using contaminated utensils, and can be transmitted through the saliva or other body fluids of people harboring the bacteria. More than half of the world is infected1 and the World Gastroenterology Organisation considers H. pylori infection to be a risk factor for developing gastritis, symptoms of functional dyspepsia, and duodenal and gastric ulcers.3 H. pylori is on the WHO priority pathogens list for R&D of new antibiotics4 due the rise in antibiotic resistance leading to increasing treatment failure. The populations with the highest prevalence of H. pylori are in Africa, Latin America, and Western Asia. That said, H. pylori is an infection of the world.1
Benefits of Pylopass™
Pylopass™ is the natural, advanced solution for people with H. pylori. Pylopass™ is safe and shows effectiveness, backed by 10+ human clinical trials. The Limosilactobacillus reuteri (formerly known as Lactobacillus reuteri) species has “Qualified Presumption of Safety” (QPS) status in the EU. The Pylopass™ strain has also been assessed to hold the self-affirmed “Generally Recognized as Safe” (GRAS) status in the US.
Clinical studies across various countries show Pylopass™ can aid in the reduction of H. pylori in the stomach and reduce gastrointestinal discomfort in people with H. pylori.5,6,7,8 Pylopass™ may also be useful in providing dietary support for people with H. pylori and has been shown to:
- Reduce stomach and gastrointestinal discomfort in people with H. pylori.6,8
- Contribute to the maintenance of normal gastric mucosa in people with H. pylori.6
- Help soothe the stomach/gut when having occasional occurrence of diarrhea due to antibiotic use.6,8
- Support digestive comfort and a healthy microbiome.5
- Help consumers maintain a healthy microbial balance.
The strain is a postbiotic by ISAPP definition9 enabling easy storage and shipping at room temperature, and has a shelf life of 36 months.
The strain is of human origin and has been successfully on the market for 10 years with plenty of untapped market potential.
Pylopass™ is manufactured according to HACCP guidelines and Novozymes OneHealth is ISO 9001 and ISO 22000 certified.
Stable at room temperature
It is stable at room temperature (storage 5-25°C).
What is the Limosilactobacillus reuteri DSM 17648 strain and how is it unique?
Pylopass™ is a One-in-a-trillion solution with the unique and patented Limosilactobacillus reuteri* DSM 17648 strain. We screened 700 Limosilactobacillus strains in our collection to find the one that specifically binds Limosilactobacillus antagonists to H. pylori. L. reuteri DSM18648, the Pylopass™ strain, was selected due to its highly specific adhesion to H. pylori in the binding assay, and for having the strongest coaggregation activity at the second screening level.
Microbial fermentation is one of Novozymes’ core competencies. Pylopass™ is produced through the fermentation of the L. reuteri DSM 17648 strain in a controlled production facility to achieve peak aggregation abilities. After fermentation, the cells are harvested, suspended in a protective matrix, and spray-dried at low temperature. This patented manufacturing process ensures an optimal flow of the Pylopass™ powder, enabling a ready-to-fill solution for our customers.
Pylopass™ consists of stabilized bacteria, so is stable at room temperature. The patented strain is currently sold in over 30 countries. As consumer and health care practitioner awareness continue to grow, there is a wealth of untouched market potential through which to leverage innovative, lifechanging solutions.
Pylopass™ and its manufacturing process are patented.
*Formerly known as Lactobacillus reuteri
How Pylopass™ works
With its highly targeted mode of action, the Pylopass™ L. reuteri DSM17648 strain recognizes and adheres to H. pylori cell surface structures, thereby forming a mass of L. reuteri DSM 17648 and H. pylori cells, known as a co-aggregate. The co-aggregates travel through the gastrointestinal system and it is thought that the reduction in H. pylori is a result of the co-aggregates being washed away. Through this elegant and sophisticated mode of action, Pylopass™ works in a safe and highly targeted way, and can help to reduce the load of H. pylori cells in the stomach.12
The consumer journey when living with H. pylori
Before identifying an H. pylori infection, consumers go through a long period of not knowing their cause of suffering.2 Patients are often misdiagnosed and experience a lack of certainty around the cause of their symptoms.2 It can be challenging to live with H. pylori while enduring abdominal pain, nausea, and bloating, and adapting to pharmaceutical interventions. Consumers are also worried about the continuous effects of H. pylori infection, amplifying their stress.
While living with the infection, dietary restrictions remain a source of frustration as they can effectively isolate the consumer from social interaction.2 Unfortunately, due to inefficient eradication of the infection11 or inappropriate advice, consumers may continue to restrict their diet for years to come.2
Let’s create something extraordinary together
If you’re ready to take your products the next level. We are here to help. From cutting edge biotechnology to specialist formulation and marketing. Whatever your dreams are for your brand. Together we can make it happen, let's talk.
Intrigued by Pylopass™? Here are a few more solutions to add to your portfolio
There is more to becoming a OneHealth partner than cutting edge technology
We are passionate about creating deep partnerships to create products that really standout. From formulation and product development to life cycle-management and range extension. Start your One-in-a-trillion journey with our OneHealth team.
Hooi JKY et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology Volume 153, Issue 2, August 2017, Pages 420-429
Novozymes consumer insights study 2018
World Gastroenterology Organisation, Global guidelines - Helicobacter pylori - May 2021: helicobacter-pylori-english-2021.pdf (worldgastroenterology.org)
World Health Organization, WHO publishes list of bacteria for which antibiotics are urgently needed, https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
Buckley, M., Lacey, S., Doolan, A. et al. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutr 4, 48 (2018). https://doi.org/10.1186/s40795-018-0257-4
Kornienko EA, Parolova NI, Ivanov SV, et al. ; 2020. Gastric microbiota and probiotics opportunities in helicobacter pylori eradication in children. Gastroenterol Hepatol Open Access, 11(1):13‒23. DOI: 10.15406/ghoa.2020.11.00407
Yang, L., Zou, A., Wu, H., Guo, H., Zhang, F., Zou, B., & Wang, J. (2021). Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori. BioMed research international, 2021, 6150628. https://doi.org/10.1155/2021/6150628
Parth, K., Prudhivi, R., Palatheeya, S., Abbas, S. K., Varsha, K., Niharika, B. V., & Lyngkhoi, B. (2021). Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy. Journal of Pharmaceutical Research International, 33(52B), 151-159. https://doi.org/10.9734/jpri/2021/v33i52B33611
Novozymes OneHealth proprietary insights
Helicobacter pylori eradication rate of standard triple therapy and factors affecting eradication rate at Bahir Dar city administration, Northwest Ethiopia: A prospective follow up study - PMC (nih.gov)